Erik Kinnman
Chief Executive Officer bei VIVESTO AB
Profil
Erik Kinnman is currently the Chief Executive Officer at Vivesto AB, Chairman at Kinnman Solutions AB, Director at Stayble AB, Director at Stayble Therapeutics AB, and Independent Director at ISR Immune System Regulation Holding AB.
He previously served as the Chief Executive Officer at Abliva AB and Sprint Bioscience AB, Chief Strategic Officer & Director-IR at Biovitrum AB, VP-Investor Relations & Director-Business Strategy at Egetis Therapeutics AB, Associate Professor at Karolinska Institutet, Analyst at Danske Bank A, and Chief Strategic Officer & Vice President at Swedish Orphan Biovitrum AB.
He also served as the Chief Medical Officer at Infant Bacterial Therapeutics AB.
Dr. Kinnman holds a doctorate from Karolinska Institutet and an MBA from Stockholm School of Economics.
Aktive Positionen von Erik Kinnman
| Unternehmen | Position | Beginn |
|---|---|---|
| STAYBLE THERAPEUTICS AB | Director/Board Member | 01.01.2020 |
| ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL) | Director/Board Member | 01.01.2022 |
| VIVESTO AB | Chief Executive Officer | 23.01.2023 |
| Kinnman Solutions AB | Chairman | 01.01.2016 |
| Stayble AB | Director/Board Member | - |
Ehemalige bekannte Positionen von Erik Kinnman
| Unternehmen | Position | Ende |
|---|---|---|
| SPRINT BIOSCIENCE AB | Chief Executive Officer | 01.01.2023 |
| ABLIVA AB | Chief Executive Officer | 03.02.2021 |
| INFANT BACTERIAL THERAPEUTICS AB | Chief Tech/Sci/R&D Officer | 01.01.2016 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 01.01.2011 |
| ░░░░░░░░░ ░░ | ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Erik Kinnman
| Karolinska Institutet | Doctorate Degree |
| Stockholm School of Economics | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 7 |
|---|---|
| ABLIVA AB | Health Technology |
| VIVESTO AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| EGETIS THERAPEUTICS AB | Health Technology |
| SPRINT BIOSCIENCE AB | Health Technology |
| INFANT BACTERIAL THERAPEUTICS AB | Health Technology |
| STAYBLE THERAPEUTICS AB | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
| Danske Bank A/S (Sweden) | Finance |
| Stayble AB | |
ISR Immune System Regulation Holding AB
 ISR Immune System Regulation Holding AB Pharmaceuticals: MajorHealth Technology ISR Immune System Regulation Holding AB engages in pharmaceutical research for the treatment of viral diseases focusing on Human Immunodeficiency Virus (HIV). It is developing ISR048 for the novel treatment of HIV. The company was founded by Yen Lundgren and Ulf Ljungblad in September 17, 2015 and is headquartered in Solna, Sweden. | Health Technology |
| Kinnman Solutions AB |
